Physician profile
Steven F Platko
NPI 1043874563
$2,634.13
in general payments reported to CMS, 2019-2025
19 companies · $366 in 2025
The $366 reported for 2025 was more than what 80% of Neurocritical Care providers received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $266 · 2021: $599 · 2022: $208 · 2023: $220 · 2024: $768 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $720.86 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $382.46 | 2020-2025 | Ultomiris |
| Ucb, INC. | $379.29 | 2023-2025 | Briviact, Zilbrysq, Rystiggo |
| Astrazeneca Pharmaceuticals Lp | $192.12 | 2024-2025 | Andexxa, Wainua |
| Genentech USA, INC. | $172.67 | 2019-2025 | Ocrevus, Enspryng |
| Jazz Pharmaceuticals INC. | $127.25 | 2023-2024 | Epidiolex |
| Emd Serono, INC. | $122.92 | 2021 | |
| Argenx US, INC. | $121.83 | 2023 | Vyvgart |
| Pfizer INC. | $73.51 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $66.00 | 2019 | |
| Lilly USA, LLC | $57.78 | 2024-2025 | Amyvid, Kisunla, Reyvow |
| Allergan, INC. | $55.53 | 2019 | |
| Lundbeck LLC | $40.38 | 2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $27.06 | 2024 | Hyqvia |
| Csl Behring | $25.47 | 2024 | Kcentra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $18.39 | 2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Sk Life Science, INC. | $18.15 | 2025 | |
| Averitas Pharma INC. | $17.20 | 2024 | Qutenza |
| Penumbra, INC. | $15.26 | 2025 | Red 72 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Platko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.